We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 14, 2012
Last Update Posted: October 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
SAIC-Frederick, Inc.
Therapeutics for Rare and Neglected Diseases (TRND)
QS Pharma
National Chung Cheng University
Infrared Imaging and Thermometry Unit, Biomedical Engineering and Physical Science Shared Resource (NIBIB)
ClinPharm Consulting, LLC
Ricerca Biosciences LLC
National Heart, Lung, and Blood Institute (NHLBI)
Cato Research
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)